Literature DB >> 26073127

Targeting mitochondrial reactive oxygen species to modulate hypoxia-induced pulmonary hypertension.

Sherry E Adesina1, Bum-Yong Kang1, Kaiser M Bijli1, Jing Ma1, Juan Cheng1, Tamara C Murphy1, C Michael Hart1, Roy L Sutliff2.   

Abstract

Pulmonary hypertension (PH) is characterized by increased pulmonary vascular remodeling, resistance, and pressures. Reactive oxygen species (ROS) contribute to PH-associated vascular dysfunction. NADPH oxidases (Nox) and mitochondria are major sources of superoxide (O(2)(•-)) and hydrogen peroxide (H(2)O(2)) in pulmonary vascular cells. Hypoxia, a common stimulus of PH, increases Nox expression and mitochondrial ROS (mtROS) production. The interactions between these two sources of ROS generation continue to be defined. We hypothesized that mitochondria-derived O(2)(•-) (mtO(2)(•-)) and H(2)O(2) (mtH(2)O(2)) increase Nox expression to promote PH pathogenesis and that mitochondria-targeted antioxidants can reduce mtROS, Nox expression, and hypoxia-induced PH. Exposure of human pulmonary artery endothelial cells to hypoxia for 72 h increased mtO(2)(•-) and mtH(2)O(2). To assess the contribution of mtO(2)(•-) and mtH(2)O(2) to hypoxia-induced PH, mice that overexpress superoxide dismutase 2 (Tg(hSOD2)) or mitochondria-targeted catalase (MCAT) were exposed to normoxia (21% O(2)) or hypoxia (10% O(2)) for three weeks. Compared with hypoxic control mice, MCAT mice developed smaller hypoxia-induced increases in RVSP, α-SMA staining, extracellular H(2)O(2) (Amplex Red), Nox2 and Nox4 (qRT-PCR and Western blot), or cyclinD1 and PCNA (Western blot). In contrast, Tg(hSOD2) mice experienced exacerbated responses to hypoxia. These studies demonstrate that hypoxia increases mtO(2)(•-) and mtH(2)O(2). Targeting mtH(2)O(2) attenuates PH pathogenesis, whereas targeting mtO(2)(•-) exacerbates PH. These differences in PH pathogenesis were mirrored by RVSP, vessel muscularization, levels of Nox2 and Nox4, proliferation, and H(2)O(2) release. These studies suggest that targeted reductions in mtH(2)O(2) generation may be particularly effective in preventing hypoxia-induced PH.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Catalase; Hydrogen peroxide; Mitochondria; NADPH oxidase; Pulmonary hypertension; ROS; SOD2; Superoxide

Mesh:

Substances:

Year:  2015        PMID: 26073127      PMCID: PMC4615392          DOI: 10.1016/j.freeradbiomed.2015.05.042

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  73 in total

1.  Therapeutic targeting of mitochondrial superoxide in hypertension.

Authors:  Anna E Dikalova; Alfiya T Bikineyeva; Klaudia Budzyn; Rafal R Nazarewicz; Louise McCann; William Lewis; David G Harrison; Sergey I Dikalov
Journal:  Circ Res       Date:  2010-05-06       Impact factor: 17.367

2.  Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation.

Authors:  Kip M Connor; Sita Subbaram; Kevin J Regan; Kristin K Nelson; Joseph E Mazurkiewicz; Peter J Bartholomew; Andrew E Aplin; Yu-Tzu Tai; Julio Aguirre-Ghiso; Sonia C Flores; J Andres Melendez
Journal:  J Biol Chem       Date:  2005-02-08       Impact factor: 5.157

Review 3.  Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH.

Authors:  J Ryan; K Bloch; S L Archer
Journal:  Int J Clin Pract Suppl       Date:  2011-08

4.  NADPH oxidase 2 mediates intermittent hypoxia-induced mitochondrial complex I inhibition: relevance to blood pressure changes in rats.

Authors:  Shakil A Khan; Jayasri Nanduri; Guoxiang Yuan; Brian Kinsman; Ganesh K Kumar; Joy Joseph; Balaraman Kalyanaraman; Nanduri R Prabhakar
Journal:  Antioxid Redox Signal       Date:  2010-10-19       Impact factor: 8.401

Review 5.  Modulation of vascular smooth muscle signaling by reactive oxygen species.

Authors:  Alicia N Lyle; Kathy K Griendling
Journal:  Physiology (Bethesda)       Date:  2006-08

6.  NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart.

Authors:  Junya Kuroda; Tetsuro Ago; Shouji Matsushima; Peiyong Zhai; Michael D Schneider; Junichi Sadoshima
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-16       Impact factor: 11.205

7.  Nox-derived ROS are acutely activated in pressure overload pulmonary hypertension: indications for a seminal role for mitochondrial Nox4.

Authors:  Giovanna Frazziano; Imad Al Ghouleh; Jeff Baust; Sruti Shiva; Hunter C Champion; Patrick J Pagano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-08       Impact factor: 4.733

Review 8.  Nox proteins in signal transduction.

Authors:  David I Brown; Kathy K Griendling
Journal:  Free Radic Biol Med       Date:  2009-07-21       Impact factor: 7.376

9.  Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production.

Authors:  Sergey I Dikalov; Anna E Dikalova; Alfiya T Bikineyeva; Harald H H W Schmidt; David G Harrison; Kathy K Griendling
Journal:  Free Radic Biol Med       Date:  2008-08-16       Impact factor: 7.376

10.  Chronic hypoxia promotes pulmonary artery endothelial cell proliferation through H2O2-induced 5-lipoxygenase.

Authors:  Kristi M Porter; Bum-Yong Kang; Sherry E Adesina; Tamara C Murphy; C Michael Hart; Roy L Sutliff
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

View more
  35 in total

1.  Enhanced Expression of Catalase in Mitochondria Modulates NF-κB-Dependent Lung Inflammation through Alteration of Metabolic Activity in Macrophages.

Authors:  Wei Han; Joshua P Fessel; Taylor Sherrill; Emily G Kocurek; Fiona E Yull; Timothy S Blackwell
Journal:  J Immunol       Date:  2020-06-29       Impact factor: 5.422

Review 2.  NADPH oxidase: its potential role in promotion of pulmonary arterial hypertension.

Authors:  Jing-Jie Peng; Bin Liu; Jin-Yun Xu; Jun Peng; Xiu-Ju Luo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-11       Impact factor: 3.000

3.  Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension.

Authors:  Hagir B Suliman; Eva Nozik-Grayck
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

4.  Rats with a Human Mutation of NFU1 Develop Pulmonary Hypertension.

Authors:  Maki Niihori; Cody A Eccles; Sergey Kurdyukov; Marina Zemskova; Mathews Valuparampil Varghese; Anna A Stepanova; Alexander Galkin; Ruslan Rafikov; Olga Rafikova
Journal:  Am J Respir Cell Mol Biol       Date:  2020-02       Impact factor: 6.914

Review 5.  Mitochondria in lung disease.

Authors:  Suzanne M Cloonan; Augustine M K Choi
Journal:  J Clin Invest       Date:  2016-03-01       Impact factor: 14.808

6.  The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age.

Authors:  Mariya T Sweetwyne; Jeffrey W Pippin; Diana G Eng; Kelly L Hudkins; Ying Ann Chiao; Matthew D Campbell; David J Marcinek; Charles E Alpers; Hazel H Szeto; Peter S Rabinovitch; Stuart J Shankland
Journal:  Kidney Int       Date:  2017-01-04       Impact factor: 10.612

7.  NADPH oxidase 4 is not involved in hypoxia-induced pulmonary hypertension.

Authors:  C Veith; S Kraut; J Wilhelm; N Sommer; K Quanz; W Seeger; R P Brandes; N Weissmann; K Schröder
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

8.  Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.

Authors:  Victor Tseng; Roy L Sutliff; C Michael Hart
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

9.  Cellular and Molecular Processes in Pulmonary Hypertension.

Authors:  Vic Maietta; Jorge Reyes-García; Vishal R Yadav; Yun-Min Zheng; Xu Peng; Yong-Xiao Wang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Hypoxia inhibits expression and function of mitochondrial thioredoxin 2 to promote pulmonary hypertension.

Authors:  Sherry E Adesina; Brandy E Wade; Kaiser M Bijli; Bum-Yong Kang; Clintoria R Williams; Jing Ma; Young-Mi Go; C Michael Hart; Roy L Sutliff
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-01-27       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.